Pioneering applications of immunotherapy in the early stages of hepatocellular carcinoma
- PMID: 38910073
- DOI: 10.1016/j.dld.2024.05.030
Pioneering applications of immunotherapy in the early stages of hepatocellular carcinoma
Erratum in
-
Erratum to "Pioneering applications of immunotherapy in the early stages of hepatocellular carcinoma" [Digestive and Liver Disease 56 (2024) 2011-2021].Dig Liver Dis. 2025 Feb;57(2):662. doi: 10.1016/j.dld.2024.12.001. Epub 2024 Dec 16. Dig Liver Dis. 2025. PMID: 39690023 No abstract available.
Keywords: Atezolizumab; Bevacizumab; HCC; Immune-checkpoint inhibitors; Immunotherapy; Liver transplantation; Systemic therapy.
Conflict of interest statement
Conflict of interest M Iavarone: Advisory Board/Speaker Bureau for Bayer, Gilead Sciences, BMS, Janssen, Ipsen, MSD, AbbVie, Guerbet, EISAI, Roche, Astra-Zeneca. Alimenti E, Lynch EN, Natola LA: no conflicts.
LinkOut - more resources
Full Text Sources